Column Group III LP Buys 15,100 Surrozen Shares, Signals Confidence in Biotech Pipeline【SZO】

Insider Buying by COLUMN GROUP III GP, LP Signals Confidence in Surrozen’s Long‑Term Potential On January 6, 2026, the general partner of Column Group III LP, Peter Svennilson, and his managing partner, Tim Kutzkey, purchased 15,100 shares of Surrozen Inc. (SZO) for $19.89 per share, bringing their holdings to 1,064,450 shares. This transaction comes on the heels of a series of purchases by the same partnership in December 2025, when they accumulated over 30,000 shares at prices ranging from $17.35 to $19.54. The recent buy is consistent with a cumulative investment of more than $250 million in SZO shares, indicating a long‑term, conviction‑driven stance rather than a short‑term speculative play.

What Does This Mean for Investors? Surrozen’s stock is highly volatile—its 52‑week high is $24.94 while its low was $5.90 last year—yet the partnership’s continued buying suggests they believe the company’s underlying biotech pipeline will deliver breakthrough therapies. The purchase price of $19.89 is only $0.13 below the most recent close of $19.97, and the share price is 30 % below the 52‑week high. For investors, this could be interpreted as a sign that a well‑capitalized, experienced investment vehicle sees value where the broader market has discounted SZO. However, the company’s negative P/E ratio (-0.89) and price‑to‑book ratio (-7.86) underscore that earnings are not yet positive, so the buy may be driven more by pipeline optimism than current profitability.

COLUMN GROUP III GP, LP – A Track Record of Patient, Pipeline‑Focused Investing COLUMN GROUP III GP, LP has a history of purchasing Surrozen shares in December 2025, acquiring 14,503 shares at $19.54, 16,381 shares at $19.54, 2,475 shares at $17.35, and 2,791 shares at $17.35. The partnership also holds a significant stake (344,827 shares) in related entities such as The Column Group Opportunity III LP. Their activity is not sporadic; it reflects a systematic, long‑term investment strategy that aligns with the maturation timelines typical of biotech development. The partnership’s managing partners are also directors on Surrozen’s board, giving them access to strategic insights that likely inform their buy decisions.

Implications for Surrozen’s Future The sustained interest from a board‑aligned investment partner suggests that Surrozen’s leadership is confident in its research agenda and commercialization strategy. If the company’s upcoming clinical milestones are achieved, the stock could see a rebound from its current $19.97 close, potentially revisiting its December high. For investors, the key watchpoints will be clinical trial updates, regulatory filings, and any new partnership announcements. In the meantime, the partnership’s buy adds a layer of downside protection, as a sizable stake can help smooth short‑term volatility.

Bottom Line COLUMN GROUP III GP, LP’s recent purchase is a strong insider endorsement that, combined with the partnership’s historical buying pattern, signals faith in Surrozen’s long‑term trajectory. While the company remains valuation‑negative, the partnership’s continued investment offers a vote of confidence that could steer the stock toward a more optimistic outlook once the biotech pipeline matures.